GM2A

From Wikipedia, the free encyclopedia
GM2 ganglioside activator

PDB rendering based on 1g13.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
SymbolsGM2A; GM2-AP; SAP-3
External IDsOMIM: 613109 MGI: 95762 HomoloGene: 349 GeneCards: GM2A Gene
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez276014667
EnsemblENSG00000196743ENSMUSG00000000594
UniProtP17900Q60648
RefSeq (mRNA)NM_000405NM_010299
RefSeq (protein)NP_000396NP_034429
Location (UCSC)Chr 5:
150.59 – 150.65 Mb
Chr 11:
55.1 – 55.11 Mb
PubMed search

GM2 ganglioside activator also known as GM2A is a protein which in humans is encoded by the GM2A gene.[1][2]

Function

The protein encoded by this gene is a small glycolipid transport protein which acts as a substrate specific co-factor for the lysosomal enzyme β-hexosaminidase A. β-hexosaminidase A, together with GM2 ganglioside activator, catalyzes the degradation of the ganglioside GM2, and other molecules containing terminal N-acetyl hexosamines.

GM2A is a lipid transfer protein that stimulates the enzymatic processing of gangliosides, and also T-cell activation through lipid presentation. This protein binds molecules of ganglioside GM2, extracts them from membranes, and presents them to beta-hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion to GM3.

It was identified as a member of ML domain family of proteins involved in innate immunity and lipid metabolism in the SMART database. .

Regulation

In melanocytic cells GM2A gene expression may be regulated by MITF.[3]

Clinical significance

Mutations in this gene, inherited in an autosomal recessive pattern, result in GM2-gangliosidosis, AB variant, a rare GM2 gangliosidosis that has symptoms and pathology identical with Tay-Sachs disease and Sandhoff disease.[4]

GM2A mutations are rarely reported, and the cases that are observed often occur with consanguineous parents or in genetically isolated populations.[5]

Because AB variant is so rarely diagnosed, even in infants, it is likely that most mutations of GM2A are fatal in the fetus in homozygotes and genetic compounds, and thus are never observed clinically.

See also

References

  1. Li SC, Nakamura T, Ogamo A, Li YT (November 1979). "Evidence for the presence of two separate protein activators for the enzymic hydrolysis of GM1 and GM2 gangliosides". J. Biol. Chem. 254 (21): 10592–5. PMID 115863. 
  2. Klima H, Tanaka A, Schnabel D, Nakano T, Schröder M, Suzuki K, Sandhoff K (September 1991). "Characterization of full-length cDNAs and the gene coding for the human GM2 activator protein". FEBS Lett. 289 (2): 260–4. doi:10.1016/0014-5793(91)81084-L. PMID 1915857. 
  3. Hoek KS, Schlegel NC, Eichhoff OM, et al. (2008). "Novel MITF targets identified using a two-step DNA microarray strategy". Pigment Cell Melanoma Res. 21 (6): 665–76. doi:10.1111/j.1755-148X.2008.00505.x. PMID 19067971. 
  4. Mahuran DJ (1999–10–8). "Biochemical consequences of mutations causing the GM2 gangliosidoses". Biochimica Biophysica Acta 1455 (2–3): 105–138. doi:10.1016/S0925-4439(99)00074-5. PMID 10571007. 
  5. "Online Mendelian Inheritance in Man". United States National Institute of Health. Retrieved 2009-04-21. 

Further reading


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.